Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study).

Jean-Baptiste AssiéRomain CorreMatteo Giaj LevraChristophe Yannick CalvetAnne-Françoise GaudinValentine GrumbergBaptiste JouanetonFrançois-Emery CottéChristos Chouaid

Published in: Therapeutic advances in medical oncology (2020)

This large nationwide retrospective real-life cohort provided narrow estimates of long-term overall survival, which reached 19% at 3 years, consistent with data from phase III trials of nivolumab. Survival rates were comparable in the three special populations of interest and the overall population.

Keyphrases

advanced non small cell lung cancer
phase iii
open label
epidermal growth factor receptor
clinical trial
cross sectional
free survival
double blind
electronic health record
big data
randomized controlled trial
combination therapy
tyrosine kinase
artificial intelligence